Acadia Pharmaceuticals - Articles and news items

FDA approves Nuplazid to treat hallucinations in Parkinson’s disease

Industry news / 3 May 2016 / Victoria White, Digital Content Producer

The FDA has approved Acadia’s Nuplazid, the first drug approved to treat hallucinations and delusions experienced by some people with Parkinson’s disease…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+